Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04557397 · ClinicalTrials.gov registry record · Phase 1
Fruquintinib CYP3A Inhibitor and Inducer Study
A Phase 1 study, sponsored by Hutchison Medipharma Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT04557397 is a Phase 1 study that has completed, run by Hutchison Medipharma Limited. The registered enrollment target is 28 participants.
The verdict
NCT04557397, a Phase 1 study, has completed, sponsored by Hutchison Medipharma Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
A study to assess the effect of itraconazole, a strong CYP3A inhibitor, and the effect of rifampin, a strong CYP3A inducer, on the pharmacokinetics of fruquintinib in healthy subjects.
Interventions
- DRUG Rifampin
- DRUG Itraconazole
- DRUG Fruquintinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2020-09-02 |
| Est. Completion | 2020-10-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04557397
The ClinicalTrials.gov registry entry for NCT04557397 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hutchison Medipharma Limited, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rifampin is the first listed.
NCT04557397 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04557397 about?
NCT04557397 is a clinical study titled "Fruquintinib CYP3A Inhibitor and Inducer Study". A study to assess the effect of itraconazole, a strong CYP3A inhibitor, and the effect of rifampin, a strong CYP3A inducer, on the pharmacokinetics of fruquintinib in healthy subjects.
What is the current status of trial NCT04557397?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2020-09-02. Estimated completion is 2020-10-18.
What interventions are being tested in trial NCT04557397?
The interventions under investigation include: Rifampin (DRUG), Itraconazole (DRUG), Fruquintinib (DRUG).
Who is sponsoring clinical trial NCT04557397?
This trial is sponsored by Hutchison Medipharma Limited, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.